{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["40(3)"],"submitter":["Bishton M"],"funding":["Celltrion Healthcare"],"pubmed_abstract":["Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen (≤90 min) in clinical practice, published data on the safety of RI of CT-P10 in patients with NHL and CLL are limited. Hence, this study collected real-world safety and effectiveness data on RI-CT-P10 from the medical records of 196 patients with NHL or CLL in 10 European centers, 6 months after the date of the first RI (index date); the infusion-related reaction (IRR) rate was compared to previously published data. Ten percent (95% confidence interval 6%-15%; n = 20/196) of patients experienced an infusion-related reaction (IRR) on day 1-2 pos"],"journal":["Hematological oncology"],"pagination":["370-380"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9545983"],"repository":["biostudies-literature"],"pubmed_title":["The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe."],"pmcid":["PMC9545983"],"pubmed_authors":["Kim S","Golfier C","Fernandez AR","Lee YN","Marshall S","Salles G","Bocchia M","Zinzani PL","Harchowal J","Sanchez Blanco JJ","Tucci A","Bishton M"],"additional_accession":[]},"is_claimable":false,"name":"The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.","description":"Rapid infusion (RI) of the rituximab biosimilar CT-P10 is currently only an approved treatment regimen for the treatment of rheumatoid arthritis. Although both CT-P10 and reference rituximab are known to be frequently administered using a RI regimen (≤90 min) in clinical practice, published data on the safety of RI of CT-P10 in patients with NHL and CLL are limited. Hence, this study collected real-world safety and effectiveness data on RI-CT-P10 from the medical records of 196 patients with NHL or CLL in 10 European centers, 6 months after the date of the first RI (index date); the infusion-related reaction (IRR) rate was compared to previously published data. Ten percent (95% confidence interval 6%-15%; n = 20/196) of patients experienced an infusion-related reaction (IRR) on day 1-2 pos","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-04T20:03:40.197Z","creation":"2025-04-04T20:03:40.197Z"},"accession":"S-EPMC9545983","cross_references":{"pubmed":["35168291"],"doi":["10.1002/hon.2978"]}}